Littérature scientifique sur le sujet « Yi jia lei »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Yi jia lei ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Yi jia lei"
1
Loh, Jia Jian, Tin Lok Wong, Shixun Lu, Helen HN Yan, Hoi Cheong Siu, Ren Xi, Dessy Chan et al. « Abstract 1755 : ADAR1-mediated RNA editing of SCD1 links lipid metabolism to gastric cancer drug resistance and self-renewal ». Cancer Research 83, no 7_Supplement (4 avril 2023) : 1755. http://dx.doi.org/10.1158/1538-7445.am2023-1755.
Texte intégralRésumé :
Abstract Targetable drivers governing to 5-fluorouracil and cisplatin (5FU+CDDP) resistance remain elusive due to the paucity of physiologically and therapeutically relevant models. Accordingly, we established 5FU+CDDP resistant intestinal subtype GC patient-derived organoid lines. JAK/STAT signaling and its downstream, adenosine deaminases acting on RNA 1 (ADAR1), are shown to be concomitantly upregulated in the resistant lines. ADAR1 was demonstrated to confer chemoresistance and self-renewal in an RNA editing-dependent manner. WES-seq coupled with RNA-seq identified enrichment of hyperedited lipid metabolism genes in the resistant lines. Mechanistically, ADAR1-mediated A-to-I editing on 3’UTR of stearoyl-CoA desaturase (SCD1) increased binding of KH domain-containing, RNA-binding, signal transduction-associated 1 (KHDRBS1), thereby augmenting SCD1 mRNA stability. Consequently, SCD1 facilitates lipid droplet formation to alleviate chemotherapy-induced ER stress and enhances self-renewal through increasing β-catenin expression. Pharmacological inhibition of SCD1 abrogated chemoresistance and tumor-initiating cell frequency. Clinically, high proteomic level of ADAR1 and SCD1, or high SCD1 editing/ADAR1 mRNA signature score predicts a worse prognosis. Together, we unveiled a novel actionable target to circumvent chemoresistance. Citation Format: Jia Jian Loh, Tin Lok Wong, Shixun Lu, Helen HN Yan, Hoi Cheong Siu, Ren Xi, Dessy Chan, Max JF Kam, Lei Zhou, Man Tong, John A. Copland, Leilei Chen, Jingping Yun, Suet Yi Leung, Stephanie Ma. ADAR1-mediated RNA editing of SCD1 links lipid metabolism to gastric cancer drug resistance and self-renewal [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1755.
2
Lin, Ying-Yi, Hong-Fei Gao, Hong Li, Bo-Lei Du, Min-Yi Cheng, Jia-Chen Zou, Xing-xing Zheng et al. « Abstract PO1-06-01 : Clinical Efficacy of Tumor Organoid-Guided Cancer Therapy for Locally Advanced Unresectable or Metastatic Breast Cancer ». Cancer Research 84, no 9_Supplement (2 mai 2024) : PO1–06–01—PO1–06–01. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-06-01.
Texte intégralRésumé :
Abstract Purpose: Patient-derived organoids (PDOs) may facilitate treatment selection, but the feasibility of using breast cancer PDOs to guide personalized treatment in clinical practice has not been fully investigated. This study aimed to assess the clinical efficacy of treatment guided by PDO drug sensitivity tests (OGT) versus treatment of physician’s choice (TPC) in patients with locally advanced unresectable or metastatic breast cancer (MBC) and to explore the potential of PDOs to reveal mechanisms underlying treatment resistance. Methods: Patients diagnosed with MBC were recruited between January 2020 and August 2022. PDOs were established from biopsies specimens or malignant effusion samples. The efficacy of customized drug panels was determined by measuring cell mortality after drug exposure. Patients receiving OGT were matched 1:2 by nearest neighbor propensity scores with patients receiving TPC. The primary clinical outcome was progression-free survival. Secondary outcomes included objective response rate and disease control rate. Targeted gene sequencing and pathway enrichment analysis were performed. Results: 46 PDOs (46 of 51, 90.2%) were generated from 45 MBC patients. PDO drug screening showed an accuracy of 81.1% (95% CI 67.6%-91.9%) in predicting patients' clinical responses. 36 OGT patients were matched to 69 TPC patients. OGT was associated with prolonged median progression-free survival (11.0 months vs 5.0 months; unadjusted hazard ratio 0.53 [95% CI 0.33-0.85]; P=0.01) and improved disease control (88.9% vs 63.8%; unadjusted odd ratio 4.26 [1.44-18.62]) compared with TPC. The objective response rate of both groups was similar. Pathway enrichment analysis uncovered differentially modulated pathways implicated in DNA repair and transcriptional regulation in patients less sensitive to capecitabine/gemcitabine, and pathways associated with cell cycle regulation in patients less sensitive to palbociclib. Conclusions: MBC patients treated with OGT were associated with superior progression-free survival and disease control compared with TPC. PDO-based functional precision medicine is a feasible strategy for treatment optimization and customization in MBC and may enhance our understanding of therapeutic resistance. Citation Format: Ying-Yi Lin, Hong-Fei Gao, Hong Li, Bo-Lei Du, Min-Yi Cheng, Jia-Chen Zou, Xing-xing Zheng, Teng Zhu, Ting-Ting Li, Sheng Li, Kun Wang. Clinical Efficacy of Tumor Organoid-Guided Cancer Therapy for Locally Advanced Unresectable or Metastatic Breast Cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-06-01.
3
Gao, Yue, Chun-Jie Liu, Hua-Yi Li, Xiao-Ming Xiong, Sjors G. j. g. In ‘t Veld, Gui-Ling Li, Jia-Hao Liu et al. « Abstract LB168 : Platelet RNA signature enables early and accurate detection of ovarian cancer : An intercontinental, biomarker identification study ». Cancer Research 82, no 12_Supplement (15 juin 2022) : LB168. http://dx.doi.org/10.1158/1538-7445.am2022-lb168.
Texte intégralRésumé :
Abstract Background: Morpho-physiological alternations of platelets provided a rationale to harness RNA sequencing of tumor-educated platelets (TEPs) for preoperative diagnosis of cancer. Timely, accurate, and non-invasive detection of ovarian cancer in women with adnexal masses presents a significant clinical challenge. Patients and Methods: This intercontinental, hospital-based, diagnostic study included 761 treatment-naïve inpatients with histologically confirmed adnexal masses and 167 healthy controls from nine medical centers (China, n=3; Netherlands, n=5; Poland, n=1) between September 2016 and May 2019. The main outcomes were the performance of TEPs and their combination with CA125 in two Chinese (VC1 and VC2) and the European (VC3) validation cohorts collectively and independently. Exploratory outcome was the value of TEPs in public pan-cancer platelet transcriptome datasets. Results: The AUCs for TEPs in the combined validation cohort, VC1, VC2, and VC3 were 0.918 (95% CI 0.889-0.948), 0.923 (0.855-0.990), 0.918 (0.872-0.963), and 0.887 (0.813-0.960), respectively. Combination of TEPs and CA125 demonstrated an AUC of 0.922 (0.889-0.955) in the combined validation cohort; 0.955 (0.912-0.997) in VC1; 0.939 (0.901-0.977) in VC2; 0.917 (0.824-1.000) in VC3. For subgroup analysis, TEPs exhibited an AUC of 0.858, 0.859, and 0.920 to detect early-stage, borderline, non-epithelial diseases and 0.899 to discriminate ovarian cancer from endometriosis. Analysis of public datasets suggested that TEPs had potential to detect multiple malignancies (Table 1). Conclusions: TEPs had robustness, compatibility, and universality for preoperative diagnosis of ovarian cancer since it withstood validations in populations of different ethnicities, heterogeneous histological subtypes, early-stage ovarian cancer as well as other malignancies. However, these observations warrant prospective validations in a larger population before clinical utilities. Table 1. Performance for TEPs in public pan-cancer datasets. Disease n Healthy Control AUC, area under the curve (95% CI) Women NSCLC (non-small-cell lung cancer) 126 77 0.758 (0.691-0.825) Breast cancer 38 77 0.817 (0.726-0.909) Colorectal cancer 18 77 0.973 (0.945-1.000) Pancreatic cancer 16 77 0.993 (0.981-1.000) Glioblastoma 10 77 0.923 (0.831-1.000) Men NSCLC 119 82 0.746 (0.677-0.815) Colorectal cancer 25 82 0.933 (0.884-0.982) Pancreatic cancer 22 82 0.993 (0.984-1.000) Glioblastoma 19 82 0.981 (0.959-1.000) All NSCLC 245 159 0.774 (0.728-0.820) Colorectal cancer 40 159 0.978 (0.961-0.996) Breast cancer 38 159 0.821 (0.736-0.906) Pancreatic cancer 35 159 0.987 (0.974-0.999) Glioblastoma 35 159 0.931 (0.890-0.972) Hepatobiliary carcinomas 14 159 0.991 (0.978-1.000) Citation Format: Yue Gao, Chun-Jie Liu, Hua-Yi Li, Xiao-Ming Xiong, Sjors G.j.g. In ‘t Veld, Gui-Ling Li, Jia-Hao Liu, Guang-Yao Cai, Gui-Yan Xie, Shao-Qing Zeng, Yuan Wu, Jian-Hua Chi, Qiong Zhang, Xiao-Fei Jiao, Lin-Li Shi, Wan-Rong Lu, Wei-Guo Lv, Xing-Sheng Yang, Jurgen M.j. Piek, Cornelis D de Kroon, C.a.r. Lok, Anna Supernat, Sylwia Łapińska-Szumczyk, Anna Łojkowska, Anna J. Żaczek, Jacek Jassem, Bakhos A. Tannous, Nik Sol, Edward Post, Myron G. Best, Bei-Hua Kong, Xing Xie, Ding Ma, Thomas Wurdinger, An-Yuan Guo, Qing-Lei Gao. Platelet RNA signature enables early and accurate detection of ovarian cancer: An intercontinental, biomarker identification study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr LB168.
4
Wu, Song-Yang, Xi Jin, Yin Liu, Wen-Jia Zuo, Li Chen, Xiyu Liu, Lei Fan et al. « Abstract PO1-14-07 : Programme of mast cell subsets to potentiate breast cancer immunotherapy : from bed to bench to bed (the phase 2 platform RENAISSANCE trial) ». Cancer Research 84, no 9_Supplement (2 mai 2024) : PO1–14–07—PO1–14–07. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-14-07.
Texte intégralRésumé :
Abstract Background: Immune checkpoint inhibitors (ICIs) have heralded a new era in breast cancer treatment; however, response rates remain limited, making precision immune-oncology a major unmet need. In addition to T cells, effective immune responses to ICIs rely on coordinated interactions between innate and adaptive immune cells. Mast cells are evolutionarily conserved, tissue-resident cells of importance to human health. Specific subsets of mast cells might be endowed with opposite roles in cancer treatment, yet the extent of mast cell heterogeneity and its clinical merit in immunotherapy remain undefined. Objective: We sought to comprehensively characterize mast cells in breast cancer, investigate their association with immunotherapy response with in-depth mechanistic insights, and identify actionable strategies to modulate mast cell functional states, thereby optimizing immunotherapy efficacy. Methods: We employed single-cell profiling on longitudinal breast cancer samples from three independent clinical trials (NCT04613674, NCT03197389 and GSE169246) to delineate mast cell heterogeneity in anti-PD-(L)1 therapy. By integrating multi-omic analyses, tissue characterization, preclinical experiments, transgenic mice, and high-throughput drug screening, we outlined the molecular features, underlying mechanisms, and clinical relevance of distinct mast cells to elicit ICI-responsive microenvironments. Subsequently, we launched RENAISSANCE (NCT05076682), a proof-of-concept, Bayesian adaptive, phase 2 platform trial, to evaluate the efficacy and safety of combining mast cell therapeutics with anti-PD-1 backbone therapy in metastatic triple-negative breast cancer (TNBC) patients who progressed after immunotherapy. The primary endpoint was the objective response rate (ORR) assessed using RECIST v1.1 criteria. Results: We identified a distinct population of mast cells termed antigen-presenting mast cells (APMCs), constituting approximately 30% of intratumoral mast cells and correlating with improved clinical benefit of anti-PD-(L)1 therapy in TNBC. APMCs displayed MHC-II and costimulatory molecules, and indicated the presence of tumor-reactive T cells and tertiary lymphoid structures. Using three immunocompetent mouse models, we confirmed the immunomodulatory capacity of APMCs in immunotherapy. Mechanistically, by employing Cpa3CreERT2Cd74fl/fl mice, we demonstrated that APMCs potentiate anti-PD-1 efficacy and antitumor T cell immunity through their antigen-presentation machinery. Interestingly, we identified cromolyn, an FDA-approved drug for allergy, as a potential therapeutic agent that elicited APMC-dependent CD8+ T cell cytotoxicity to synergize with anti-PD-1 therapy. Between February 2022 and March 2023, 10 patients with immunotherapy-refractory metastatic TNBC were enrolled to receive cromolyn plus camrelizumab backbone treatment. Given Bayesian predictive probability, this arm was “graduated” due to meeting the pre-specified efficacy boundary, with an ORR of 40.0% (4/10). The treatment was well tolerated with similar safety profiles of relevant drugs. Conclusions: Our findings provide crucial insights into the impact of mast cell heterogeneity on the clinical response to ICIs at a single-cell level, and pave the way for APMC-directed therapeutic interventions in cancer treatment. To our knowledge, this is the first prospective study in breast cancer of cromolyn plus anti-PD-1 backbone regimen after anti-PD-(L)1 immunotherapy failure, demonstrating significant antitumor activity and commendable tolerability. Consequently, we suggest a phase 3 randomized study to consolidate this finding, which might be an effective treatment in patients for whom there are few effective treatment options. Citation Format: Song-Yang Wu, Xi Jin, Yin Liu, Wen-Jia Zuo, Li Chen, Xiyu Liu, Lei Fan, Zhong-Hua Wang, Yan-Fei Liu, Yi-Zhou Jiang, Zhi-Ming Shao. Programme of mast cell subsets to potentiate breast cancer immunotherapy: from bed to bench to bed (the phase 2 platform RENAISSANCE trial) [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-14-07.
5
Kuo, Wen-Hung, Yen-Jang Huang, Jia-Yang Chen, Yi-Chun Wu, Chia-Chun Chen, Mark D. Pegram et Ying-Chih Chang. « Abstract LB434 : Rapid and reproducible expansion of rare tumor cells : The R3CE platform for personalized medicine ». Cancer Research 84, no 7_Supplement (5 avril 2024) : LB434. http://dx.doi.org/10.1158/1538-7445.am2024-lb434.
Texte intégralRésumé :
Abstract We have developed a novel single-cell derived 3D organoid culture platform, Rapid, Reproducible, Rare Cell 3D Expansion (R3CE), capable of generating 3D organoids from solid tumors and normal tissues obtained via surgical tissues and needle biopsies within one week. This method demonstrates over 90% success in banking for at least two passages with over 106 cells across various cancer types, including breast cancer, colorectal cancer, hepatoma cancer, and ovarian cancer. The organoids maintain high fidelity to original tissues, as evidenced by H&E staining, WES, and protein marker analysis across generations. Notably, the R3CE platform can also cultivate circulating tumor cells (CTCs) from peripheral blood. The drug sensitivity profiles of RCE-cultured CTCs closely mirrored clinical outcomes in breast cancer patients. For a patient with stage IV HER2-positive breast cancer, our real-time assay results led to an adjustment in treatment from lapatinib/5-FU to lapatinib/Trastuzumab emtansine (TDM-1), which resulted in substantial clinical improvement. To our knowledge, the R3CE platform is the first 3D organoid system that does not require aggregation or 3D scaffold such as matrigel system. These advancements position the R3CE platform as a promising tool for personalized medicine, offering a rapid and accurate method for drug screening and therapeutic response prediction to guide clinical decision-making in cancer treatment. Citation Format: Wen-Hung Kuo, Yen-Jang Huang, Jia-Yang Chen, Yi-Chun Wu, Chia-Chun Chen, Mark D. Pegram, Ying-Chih Chang. Rapid and reproducible expansion of rare tumor cells: The R3CE platform for personalized medicine [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr LB434.
6
Huang, Yu-zhou, Ming-Yi Sang, Pei-Wen Xi, Ruo-Xi Xu, Meng-Yuan Cai, Zi-Wen Wang, Jian-Yi Zhao, Yi-Han Li, Ji-Fu Wei et Qiang Ding. « Abstract 7220 : Emerging combination strategy : FANCI suppression induces PARP1 redistribution to enhance efficacy of PARP inhibitors in breast cancer ». Cancer Research 84, no 6_Supplement (22 mars 2024) : 7220. http://dx.doi.org/10.1158/1538-7445.am2024-7220.
Texte intégralRésumé :
Abstract While polyADP-ribose polymerase (PARP) inhibitors have made advancements in the treatment of breast cancer, challenges such as chemotherapy resistance and limited application persist. Fanconi AnemiaComplementation Group I (FANCI), a DNA repair protein associated with breast cancer development, represents a potential target for novel combination therapeutic strategies. However, the role of FANCI in breast cancer and its impact on the efficacy of PARP inhibitors require further investigation. In our study, we analyzed FANCI expression in breast cancer tissues and cell lines, and its correlation with clinical parameters and patient prognosis. Lentiviral vectors were utilized and functional assays were performed to evaluate the effects of FANCI modulation on breast cancer cell growth and migration. Co-immunoprecipitation assays and protein interaction analysis were conducted to identify the interaction between FANCI and PARP1 and determine the specific binding region. The functionality and nuclear distribution of PARP1 were assessed upon FANCI modulation. Finally, the sensitivity of breast cancer cells to the PARP inhibitor talazoparib upon FANCI knockdown was evaluated in vitro and in vivo. Our findings demonstrated that FANCI was overexpressed in breast cancer and associated with poor prognosis. FANCI significantly promoted breast cancer cell proliferation both in vitro and in vivo. We identified the interaction between FANCI and PARP1, specifically at the FANCI helical domain 2 binding site. FANCI knockdown led to reduced nuclear localization of PARP1 and decreased PARP1 activity. Importantly, combination treatment with FANCI knockdown and talazoparib significantly inhibited cancer growth in vitro and in vivo. Additionally, we found that the cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib, which effectively suppresses FANCI protein expression, exhibited a robust synergistic effect with talazoparib both in vitro and in vivo. In conclusion, FANCI is a novel therapeutic target for breast cancer. Suppression of FANCI regulates PARP1 redistribution and activity, making breast cancer cells more responsive to PARP inhibitors. This combination therapeutic strategy shows potential in enhancing the effectiveness of PARP inhibitors for breast cancer treatment, regardless of BRCA mutations. Citation Format: Yu-zhou Huang, Ming-Yi Sang, Pei-Wen Xi, Ruo-Xi Xu, Meng-Yuan Cai, Zi-Wen Wang, Jian-Yi Zhao, Yi-Han Li, Ji-Fu Wei, Qiang Ding. Emerging combination strategy: FANCI suppression induces PARP1 redistribution to enhance efficacy of PARP inhibitors in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7220.
7
Tong, Jie, et Ji Ma. « A preliminary study on a Mirror of Japan (Ribenyijian) ». Trans/Form/Ação 45, no 4 (décembre 2022) : 117–36. http://dx.doi.org/10.1590/0101-3173.2022.v45n4.p117.
Texte intégralRésumé :
Abstract: After the reign of Emperor Jiajing of the Ming Dynasty, as the Japanese pirates’ problem became more and more serious, books devoted to the study of Japan began to be published. Among them, the most important ones are A Brief Survey of Japan (Ri Ben Kao Lue), A Compilation of Japanese Maps (Ri Ben Tu Zuan), A Mirror of Japan (Ri Ben Yi Jian), A Survey of Japan (Ri Ben Kao), A Record of Japanese Customs (Ri Ben Fen Tu Ji), and A Biography of Japanese Pirates in Qiantai (Qian Tai Wo Zhuan). Out of these, A Mirror of Japan is a special one. In addition, there are also special books that depict the general ambiance of Japan, such as A Collection of Coastal Military Maps (Chou Hai Tu Bian), Resistance to Japanese Pirates in Ming Dynasty (Huang Ming Yu Wo Lu), the Compilation of Coastal Defense (Hai Fang Zuan Yao) and the Continuation of Coastal Defense Category in Zhedong and Zhexi Regions (Liang Zhe Hai Fang Lei Kao Xu Bian). Zheng Shungong, the author of the book A Mirror of Japan, visited Japan twice, so many contents in the book are based on his own experience and knowledge. Therefore, the breadth and scope of his research on Japan had gone beyond the similar literature of the Ming Dynasty. Moreover, the Japanese pirates’ record and analysis in the book are of great research value. Before the publication of Huang Zunxian’s Annals of Japan (Ri Ben Tu Zhi), A Mirror of Japan was one of the highest levels of monographs on Japan in ancient China.
8
Wang, Lei, Yufeng Xiao, Yuewan Luo, Rohan Master, Jiao Mo, Myung-Chul Kim, Yi Liu et al. « Abstract 2469 : PROTAC mediated NR4A1 degradation as a novel strategy for cancer immunotherapy ». Cancer Research 84, no 6_Supplement (22 mars 2024) : 2469. http://dx.doi.org/10.1158/1538-7445.am2024-2469.
Texte intégralRésumé :
Abstract An effective cancer therapy requires both killing cancer cells and targeting tumor-promoting pathways or cell populations within the tumor microenvironment (TME). We purposely search for molecules that are critical for multiple cell types in the TME and identified nuclear receptor subfamily 4 group A member 1 (NR4A1) as one such molecule. NR4A1 has been shown to promote the aggressiveness of cancer cells and maintain the immune suppressive TME. Using genetic and pharmacological approaches, we establish NR4A1 as a valid therapeutic target for cancer therapy. Importantly, we have developed the first-of-its kind proteolysis-targeting chimera (PROTAC, named NR-V04) against NR4A1. NR-V04 effectively degrades NR4A1 within hours of treatment in vitro and sustains for at least 4 days in vivo, exhibiting long-lasting NR4A1-degradation in tumors and an excellent safety profile. NR-V04 leads to robust tumor inhibition and sometimes eradication of established melanoma tumors. At the mechanistic level, we have identified an unexpected novel mechanism via significant induction of tumor-infiltrating (TI) B cells as well as an inhibition of monocytic myeloid derived suppressor cells (m-MDSC), two clinically relevant immune cell populations in human melanomas. Overall, NR-V04-mediated NR4A1 degradation holds promise for enhancing anti-cancer immune responses and offers a new avenue for treating various types of cancer such as melanoma. Citation Format: Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan Master, Jiao Mo, Myung-Chul Kim, Yi Liu, Chandra Maharjan, Urvi Patel, Xiangming Li, Donald Shaffer, Guertin Kevin, Haoyang Zhuang, Emily Moser, Keiran Smalley, Daohong Zhou, Guangrong Zheng, Weizhou Zhang. PROTAC mediated NR4A1 degradation as a novel strategy for cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2469.
9
CHOI, Haebyoul. « The Perception and Treatment of People about Abscesses(<i>癰疽</i>) in the Song Period : Focus on Hongmai(<i>洪邁</i>) <i>Yijianzhi</i>(<i>夷堅志</i>) ». Korean Journal of Medical History 33, no 1 (30 avril 2024) : 135–89. http://dx.doi.org/10.13081/kjmh.2024.33.135.
Texte intégralRésumé :
During the Song period, abscesses(<i>癰疽</i>) were a disease that could affect anyone regardless of their class. This study examines how people at that time explained the cause of abscesses and their efforts to treat them, focusing on the experiences of those who suffered from abscesses and their families. Previous research on disease history during the Song period primarily focused on ailments like colds (<i>傷寒</i>) and infectious diseases (<i>瘟疫</i>), or plagues prevalent in the southern regions of China. On the other hand, examining abscesses as a common everyday illness that could affect anyone and considering them from the perspective of patients’ experiences has remained unexplored in previous studies.</br>To reconstruct the experiences of Song period patients, this study analyzes over sixty anecdotes related to abscesses found in <i>Yi Jian Zhi</i> (<i>夷堅志</i>) written by Hong Mai. These cases span across the mid to late 12th century, with a majority of the patients being from the literati (<i>士人</i>) class or connected to the literati.</br>These anecdotes exhibit two distinct trends. One focuses on narratives surrounding the onset of abscesses, attributing their cause primarily to the patients’ lifestyle. When the cause of the abscesses was unknown, people metaphorically attributed its onset to perceived blasphemy against God, an act of killing, negligence in duties, or other wrongdoings. This trend is evident among the literati class in particular, where abscesses were often linked to factors such as excessive legal executions or exploitation, and even acts of killing people. Except for those cases, in explaining the cause of abscesses in commoners, there were instances caused by a pediculus infestation, while in case of literati, Dansha (<i>丹砂</i>) poisoning was a common cause. It is interesting to note that the narrative tradition, prevalent in official history biographies, which attributes the onset of abscesses to worries and resentment, was not evident in written records such as <i>Yi Jian Zhi</i>. Furthermore, the detailed description of external similarities, portraying abscesses as traces of punishment from the underground realm (<i>陰界</i>), is a narrative characteristic that solidified such stereotypical perceptions. The literati's notion that they should alert people through these related anecdotes contributed to the spread of this perception.</br>Another trend in these anecdotes was centered around narratives of abscess treatment, where the focus shifted primarily to seeking “doctors,” unlike the metaphorical explanations of abscess onset causes and processes. When afflicted with abscesses, people generally sought out those renowned surgeons, known as Yang-yi (<i>瘍醫</i>), and those famous for treating abscesses. In local communities, individuals who had “received the divine secrets of abscesses,” those possessing their own mysterious abscesses cures, and those famous for generations for treating abscesses by using stone acupuncture were active. Such information about them was shared within the local societies. Their treatment predominantly consisted of surgical procedures to lance abscesses and drain pus, which often led patients to endure significant pain during the treatment process. In many cases, such patients sought treatment from well-known local surgeons and abscess specialists who surgically treated them. The literati, who are said to have influenced the development of pulse-centered medical and academic medicine in China, also sought out surgeons for abscess treatment.</br>Medical formularies compiled by the court as well as privately published ones rarely mentioned surgical methods utilizing tools. The fact that surgical techniques were utilized in local regions at that time indicates a disparity between the official medical practices documented in texts and the practical methods employed in local communities.</br>An analysis of approximately sixty anecdotes related to abscesses shows that abscesses were characterized by unknown causes and excruciating pain. Their onset was often attributed to the patient’s lifestyle and wrongdoings, and they were also perceived as punishment for one’s wrongdoings. However, as it was a disease where treatment effects could be relatively easily observed through surgical procedures, there was a proactive utilization of the locally formed treatment environment, preferring surgical interventions over relying on religious powers. Contrary to the medical trends and methods outlined in medical literature, surgical treatments were prevalent as the chosen method of treatment among the population in local communities. It appears that the realities experienced, reasoned, and shared by people in the Song period regarding the perception and response to abscesses did not necessarily align with those of mainstream medical practices. Moreover, despite attributing the onset of abscesses to one’s wrongdoing, there was a preference for seeking surgeons or Yang-yi (<i>瘍醫</i>) over religious methods in their treatment, reflecting a characteristic of the local medical culture surrounding abscesses during the Song period.
10
Kang, Sungmuk, Hyeonju Kang, Jihye Koo, Yoojin Kim, Suho Park, Inyoung Lee, Jiye Yi et al. « Abstract 1532 : Next generation IgM antibody based multimeric platform : ePENDY (engineered pentamer body) ». Cancer Research 83, no 7_Supplement (4 avril 2023) : 1532. http://dx.doi.org/10.1158/1538-7445.am2023-1532.
Texte intégralRésumé :
Abstract Among many candidates from the recent diverging research to develop a multivalent platform, IgM has shown potential as a pharmaceutical because of its avidity coming from natural multimeric target binding ability. IgM has a great advantage of naturally forming multimers, however, there are some unfulfilled needs to become a good pharmaceutical platform, such as limited biological activity, short half-life, safety concerns, and difficult purification steps compared to IgG. Here, we developed an antibody platform, ePENDY, by engineering IgM to improve efficacy, safety, and convenience of manufacturing process. ePENDY has a self-assembling decavalent pentameric structure and it is an improved IgM with maximized biological activity as therapeutics by using flexible linkers. In addition, ePENDY was engineered one of the effector functions of antibodies, ADCC, was greatly increased compared to IgG as well as IgM which does not have this function. More importantly, the presence or absence of effector functions can be controlled depending on the MoA (Mode of action) of the target. Serum half-life of ePENDY was significantly increased compared to natural IgM, and ePENDY showed similar PK profiles as the IgG Fc-based molecules through FcRn recycling. Unlike natural IgM, ePENDY does not bind to any IgM receptors, such as pIgR, FcμR, and Fcα/μR, thereby eliminating possible side effects. In addition, it has been confirmed that ePENDY showed a comparable expression level to that of IgG, and since the purification process can also be set up in a process like IgG, thus production of ePENDY can be facilitated. Based on these results, we are researching ePENDY which are applying various therapeutic molecules, such as antibodies, protein ligand-based active molecules and therapeutic cancer vaccines. We expect that our versatile applicable platform, safe and long acting ePENDY, can be a superior tool for the various therapeutic targets. Citation Format: Sungmuk Kang, Hyeonju Kang, Jihye Koo, Yoojin Kim, Suho Park, Inyoung Lee, Jiye Yi, Hong Jai Lee, Yonghyun Cho, Hyunju Hwang, Kyunggi Hyun, Chungmin Lee, Gyongsik Ha. Next generation IgM antibody based multimeric platform: ePENDY (engineered pentamer body) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1532.
Thèses sur le sujet "Yi jia lei"
1
Chen, Xiaoming. « Lei feng shi xing guan jie yan de Zhong yi lin chuang yan jiu jin zhan / ». click here to view the abstract and table of contents, 2006. http://net3.hkbu.edu.hk/~libres/cgi-bin/thesisab.pl?pdf=b19986245a.pdf.
Texte intégral
2
Tan, Jianglin. « Jing ji zi you hua yi lai Taiwan jin rong gai ge yan jiu ». Hefei Shi : Hefei gong ye da xue chu ban she, 2005. http://www.loc.gov/catdir/toc/chi0701/2006409279.html.
Texte intégral
3
Li, Liming. « Cong gong jiang dao yi shu jia : Qing mo yi lai Guangdong Shiwan tao ci cong ye yuan de shen fen di wei jian gou / ». View abstract or full-text, 2005. http://library.ust.hk/cgi/db/thesis.pl?HUMA%202005%20LI.
Texte intégral
4
Lee, Shung-wai. « Mixing narratives and commentaries reading the "Leizhuan" of Shiji = Xu shi yu yi lun zhi jian : "Shi ji" "Lei zhuan" de jie du / ». Click to view the E-thesis via HKUTO, 2009. http://sunzi.lib.hku.hk/hkuto/record/B4269453X.
Texte intégral
5
Luk, Yu-shing. « A study of Yue Fei studies since late Qing Qing mo yi lai zhi Yue Fei yan jiu / ». Click to view the E-thesis via HKUTO, 1995. http://sunzi.lib.hku.hk/hkuto/record/B31950838.
Texte intégral
6
Ling-XinChen et 陳靈心. « A study on the Lei Xie and Qi Jian Yi Wen Bi Po Cong Cuo ». Thesis, 2019. http://ndltd.ncl.edu.tw/handle/v4kxf2.
Texte intégralRésumé :
碩士國立成功大學
中國文學系
107
Lei Xie is a novelist and poet in the middle of the Ming Dynasty. He was born in a famous family of imperial examinations in northern Fujian. He was very confident in his talents when he was young, but he became a county magistrate in Guangxi until he was old. Five years later, he resigned and returned home because he couldn’t stand the darkness of the officialdom. In his hometown, he is mainly engaged in the business of the family and established the Nangu Academy. He eventually died in his hometown Jian'an at the age of 79. His existing works include Qi Jian Yi Wen Bi Po Cong Cuo（奇見異聞筆坡叢脞） and Nan Gu Shi Hua（南谷詩話）. He also wrote articles and poems that were kept in the genealogy of his family. Qi Jian Yi Wen Bi Po Cong Cuo is a Legends of the Ming Dynasty he wrote before 37 years old. This is a rare fiction, only one in China, and is now kept in the National Library of Beijing. It contains 24 stories, each of which is between 1000 and 2000. It mainly tells the story of morality and ghosts that occurred at the end of the Yuan Dynasty and the beginning of the Ming Dynasty. This master's thesis mainly studies the life story of Lei Xie, as well as the motivation, main content, material source, theme and artistic characteristics of this fictions.
7
Lutovská, Tereza. « Reflexe identity v literatuře etnických Korejců v Japonsku ». Master's thesis, 2018. http://www.nusl.cz/ntk/nusl-384196.
Texte intégralRésumé :
This thesis concentrates on literary works written by writers belonging to the resident Korean minority in Japan (zainichi Koreans). Through the use of postcolonial methodology, this work attempts to monitor the development and changes in the complex concept of "identity" in works written between the 1960s and 2010. The thesis is divided into two major parts. The first, theoretical part, explains the birth of the minority, the conflicts that influenced it and the changes it went through during its history. Postcolonial methodology is also explained, with focus put on the parts that are relevant to Japan. The second, practical part of the thesis, shortly explains the history of zainichi literature and then concentrates on five important postwar resident Korean writers - Ri Kaisei, Kin Kakuei, Yi Yang-ji, Kaneshiro Kazuki and Yu Miri. It analyzes between one and four works by each author and attempts to identify changes in the perception of "identity". It also takes into account female characters and the way they are portrayed by the authors and also the language the book is written in, focusing on whether the author chooses to incorporate the Korean language into the text.
Livres sur le sujet "Yi jia lei"
1
Lin, Shulian. Jian yi jia chang tang lei = : Easy home made soup. Taibei Xian Tucheng Shi : Zhong wen chu ban she, 2002.
Trouver le texte intégral
2
Wilson, Edward Osborne. Ren lei cun zai de yi yi : Yi ge sheng wu xue jia de si suo. Taibei Shi : Ru guo chu ban she, 2016.
Trouver le texte intégral
3
F. B. M. de Waal. Ren lei de yuan xing : Yi wei quan wei de ling zhang lei dong wu jia dui ren lei de jie du. Shanghai Shi : Shanghai ke xue ji shu wen xian chu ban she, 2007.
Trouver le texte intégral
4
Shu, Xu, dir. Guo jia tu shu guan cang gu ji yi shu lei bian. Beijing : Beijiing tu shu guan chu ban she, 2004.
Trouver le texte intégral
5
Huiying, Liao, dir. Yue de ling yi mian : Yi wei ren lei xue jia de ri ben guan cha. Tai bei shi : Xing ren wen hua shi yan shi, 2011.
Trouver le texte intégral
6
Jiarimuji. Ji ming zhi nian : Yunnan Xiaoliangshan jia nu an zhi de ren lei xue yan jiu. Beijing : Zhongguo she hui ke xue chu ban she, 2019.
Trouver le texte intégral
7
Xu, Wolun. "Zu yin" bo yi yu yi yi jian gou : Dali Bai zu "bu zhao bu jia" hun yin de ren lei xue yan jiu. Beijing : She hui ke xue wen xian chu ban she, 2019.
Trouver le texte intégral
8
Feng, Sha. Yi shu zai bie chu : Dui Zhongguo dang dai lü Fa yi shu jia de ren lei xue yan jiu. Beijing : Shang wu yin shu guan, 2018.
Trouver le texte intégral
9
Daguang, Li, dir. Da guo de zun yan : Gou zhu er shi yi shi ji guo jia an quan de jian gu bao lei. Shenzhen Shi : Hai tian chu ban she, 1999.
Trouver le texte intégral
10
Linglong, Lü, et Luosangdaoji, dir. Yue liang xi chen de di fang : Yi ge ren lei xue jia zai Ali wu ren qu de xing zou chen yin. Chengdu : Sichuan min zu chu ban she, 2005.
Trouver le texte intégralRapports d'organisations sur le sujet "Yi jia lei"
1
Pretorius, Philip Christo, et Radoslav Valev. Forces Shaping Populism, Authoritarianism and Democracy in South Korea, North Korea and Mongolia. European Center for Populism Studies (ECPS), avril 2024. http://dx.doi.org/10.55271/rp0054.
Texte intégralRésumé :
This report encapsulates the highlights of the eleventh event hosted by the European Center for Populism Studies (ECPS) as part of its monthly Mapping European Populism (MGP) panel series. Titled “Forces Shaping Populism, Authoritarianism, and Democracy in South Korea, North Korea, and Mongolia,” this event unfolded online on March 30, 2024. The esteemed Dr. John Nilsson-Wright expertly moderated the panel, which boasted insights from five distinguished scholars in the field of populism. The panelists featured in the event included experts such as Dr. Joseph Yi, an Associate Professor of Political Science at Hanyang University, Seoul, renowned for his work on "Discourse Regimes and Liberal Vehemence." Dr. Meredith Rose Shaw, an Associate Professor at the Institute of Social Science, The University of Tokyo, provided valuable insights into the regional context through her research on "Foreign Threat Perceptions in South Korean Campaign Discourse: Japan, North Korea, and China." Dr. Sang-Jin Han, an Emeritus Professor of Sociology at Seoul National University, shared his expertise on sociopolitical trends in South Korea, focusing on the "Transformation of Populist Emotion in Korean Politics from 2016 to 2024." Dr. Junhyoung Lee, a Research Professor in the School of International Relations at the University of Ulsan, South Korea, contributed with his research on "Nationalism and Resilience of Authoritarian Rule in North Korea." Lastly, Dr. Mina Sumaadii, a Senior Researcher at the Sant Maral Foundation, Ulaanbaatar, Mongolia, offered a unique perspective on "Populist Nationalism as a Challenge to Democratic Stability in Mongolia." The panel served as a platform for a rich exchange of ideas and analysis, shedding light on the complex interplay between populism, authoritarianism, and democracy within these East Asian nations.